British Journal of Cancer · 2001 · 72 citations · 29 references
MedicineGeneticsOncologyCancer GeneticsMetastasisOncogenesCancer CytogeneticsLoss Of HeterozygosityMalignant NeoplasmsMyc Family OncogenesOncogene AmplificationOncogene MutationsAlterationAmplificationChromosome 3P LossMolecular Diagnostic MarkersMolecular Prognostic MarkersNeuroblastoma BiologyPrognostic Marker AssessmentPrognostic Marker Evaluation
Neuroblastoma is a heterogeneous tumour and its effective clinical management is dependent on accurate prognostic evaluation. In approximately 25% of patients amplification of the MYCN oncogene is known to be associated with a poor outcome. In order to identify additional molecular markers with prognostic potential in non-MYCN-amplified neuroblastomas, we looked for a correlation between clinical outcome and loss of heterozygosity (LOH) on four chromosomes that frequently show alteration in neuroblastoma (chromosomes 3, 4, 11 and 14). Chromosome 11q loss (with frequent parallel loss of chromosomes 3p, 4p and/or 14q) was found exclusively in tumours without MYCN amplification and was significantly associated with poor event-free survival. The 2-year event-free survival rate for 11q LOH cases was 30%, compared to 34% for MYCN-amplified cases and 100% for cases without these abnormalities. While 11q LOH was associated predominantly with advanced-stage disease, 2 cases with low-stage disease and 11q LOH both suffered relapses. We conclude that chromosome 11q loss defines a biologically distinct group of tumours without MYCN amplification that appear to have potential for aggressive metastatic growth. Thus this genetic alteration may be an important new prognostic marker in neuroblastoma.
29
Gain of Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma
Nick Bown, Simon Cotterill, Maria Łastowska et al. · New England Journal of Medicine · 1999 · 546 citations
Life Sciences, Genetics, Oncology +17
Conrad T. O. Fong, Nicholas C. Dracopoli, Peter S. White et al. · Proceedings of the National Academy of Sciences · 1989 · 397 citations · Full text
Brodeur Gm, Jon Pritchard, Frank Berthold et al. · PubMed · 1994 · 392 citations
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas
Chun Guo, Peter S. White, Matthew J. Weiss et al. · Oncogene · 1999 · 249 citations